These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 25404585

  • 21. Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease.
    Aida Y, Abe H, Tomita Y, Nagano T, Seki N, Sugita T, Itagaki M, Ishiguro H, Sutoh S, Aizawa Y.
    Int J Clin Exp Med; 2014; 7(11):4191-8. PubMed ID: 25550930
    [Abstract] [Full Text] [Related]

  • 22. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    Ooi GJ, Meikle PJ, Huynh K, Earnest A, Roberts SK, Kemp W, Parker BL, Brown W, Burton P, Watt MJ.
    J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
    [Abstract] [Full Text] [Related]

  • 23. Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells.
    Kado A, Tsutsumi T, Enooku K, Fujinaga H, Ikeuchi K, Okushin K, Moriya K, Yotsuyanagi H, Koike K.
    J Gastroenterol; 2019 Aug; 54(8):730-741. PubMed ID: 30830270
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
    Corey KE, Pitts R, Lai M, Loureiro J, Masia R, Osganian SA, Gustafson JL, Hutter MM, Gee DW, Meireles OR, Witkowski ER, Richards SM, Jacob J, Finkel N, Ngo D, Wang TJ, Gerszten RE, Ukomadu C, Jennings LL.
    J Hepatol; 2022 Jan; 76(1):25-33. PubMed ID: 34600973
    [Abstract] [Full Text] [Related]

  • 30. Serum C16:1n7/C16:0 ratio as a diagnostic marker for non-alcoholic steatohepatitis.
    Yamada K, Mizukoshi E, Seike T, Horii R, Terashima T, Iida N, Kitahara M, Sunagozaka H, Arai K, Yamashita T, Honda M, Takamura T, Harada K, Kaneko S.
    J Gastroenterol Hepatol; 2019 Oct; 34(10):1829-1835. PubMed ID: 30864239
    [Abstract] [Full Text] [Related]

  • 31. Serum thymosin beta4 as a noninvasive biomarker in patients with nonalcoholic steatohepatitis.
    Jiang Y, Han T, Zhang ZG, Zhang Y, Qi FX.
    Rev Esp Enferm Dig; 2018 Jan; 110(1):19-24. PubMed ID: 29271227
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Nonalcoholic fatty liver disease test: an external validation cohort.
    Polyzos SA, Papaefthymiou A, Doulberis M, Kountouras J.
    Hormones (Athens); 2024 Mar; 23(1):131-136. PubMed ID: 37953360
    [Abstract] [Full Text] [Related]

  • 35. Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH.
    Del Ben M, Overi D, Polimeni L, Carpino G, Labbadia G, Baratta F, Pastori D, Noce V, Gaudio E, Angelico F, Mancone C.
    Int J Mol Sci; 2018 Feb 18; 19(2):. PubMed ID: 29463024
    [Abstract] [Full Text] [Related]

  • 36. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?
    Alkhouri N, Feldstein AE.
    Metabolism; 2016 Aug 18; 65(8):1087-95. PubMed ID: 26972222
    [Abstract] [Full Text] [Related]

  • 37. Eicosanoids in Nonalcoholic Fatty Liver Disease (NAFLD) Progression. Do Serum Eicosanoids Profile Correspond with Liver Eicosanoids Content during NAFLD Development and Progression?
    Maciejewska D, Drozd A, Skonieczna-Żydecka K, Skórka-Majewicz M, Dec K, Jakubczyk K, Pilutin A, Stachowska E.
    Molecules; 2020 Apr 27; 25(9):. PubMed ID: 32349225
    [Abstract] [Full Text] [Related]

  • 38. S100A9: A Potential Biomarker for the Progression of Non-Alcoholic Fatty Liver Disease and the Diagnosis of Non-Alcoholic Steatohepatitis.
    Liu X, Wang Y, Ming Y, Song Y, Zhang J, Chen X, Zeng M, Mao Y.
    PLoS One; 2015 Apr 27; 10(5):e0127352. PubMed ID: 25993652
    [Abstract] [Full Text] [Related]

  • 39. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers.
    Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Mori K, Tanaka S, Yamada M, Akita M, Mizutani K, Fujii H, Yamamoto A, Takamatsu S, Yoshida Y, Itoh Y, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E.
    Hepatology; 2015 Nov 27; 62(5):1433-43. PubMed ID: 26199205
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.